Drug Trial Radar · NCT00077610
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients
Last checked: Nov 20, 2026Latest source record: Jan 13, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
673
Actual
Start
Feb 2004
Primary completion
Aug 2005
Study completion Aug 2005
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Feb 13, 2004
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will assess the efficacy and safety of intravenous Mircera, given as maintenance treatment for renal anemia in chronic kidney disease patients on dialysis who were previously receiving iv epoetin. The anticipated time on study treatment is 1-2 years and the target sample size is 100-500 individuals.
Conditions
- Anemia
Interventions
Epoetin alfa or betaDrug
intravenously 3 times weekly for 52 weeks, as prescribed
RO0503821 (1x/2 Weeks)Drug
60, 100, or 180 microgram (mcg) (starting dose) once every two weeks intravenously for 52 weeks.
RO0503821 (1x/4 Weeks)Drug
120, 200 or 360 mcg (starting dose) once every four weeks intravenously for 52 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Change in Hemoglobin (Hb) Concentration From Baseline to Evaluation PeriodTime frame: Baseline, Week 29 to Week 36
Locations
99 sites in 8 countries. Site status is shown where the registry gives one.
Site not named
Birmingham, Alabama
Site not named
Mobile, Alabama
Site not named
Montgomery, Alabama
Site not named
Encino, California
Site not named
Irvine, California
Site not named
Los Angeles, California
Site not named
Monterey Park, California
Site not named
Riverside, California
Site not named
Sacramento, California
Site not named
San Diego, California
Site not named
San Diego, California
Site not named
San Francisco, California
Site not named
San Jose, California
Site not named
Colorado Springs, Colorado
Site not named
Denver, Colorado
Site not named
Lakewood, Colorado
Site not named
Ocala, Florida
Site not named
Pembroke Pines, Florida
Site not named
Atlanta, Georgia
Site not named
Augusta, Georgia
Site not named
Chicago, Illinois
Site not named
Maywood, Illinois
Site not named
Louisville, Kentucky
Site not named
Covington, Louisiana
Site not named
Boston, Massachusetts
Site not named
Boston, Massachusetts
Site not named
Springfield, Massachusetts
Site not named
Detroit, Michigan
Site not named
Brooklyn Center, Minnesota
Site not named
Paterson, New Jersey
Site not named
Albuquerque, New Mexico
Site not named
Brooklyn, New York
Site not named
Great Neck, New York
Site not named
Mineola, New York
Site not named
New York, New York
Site not named
New York, New York
Site not named
Stony Brook, New York
Site not named
The Bronx, New York
Site not named
Chapel Hill, North Carolina
Site not named
Raleigh, North Carolina
Showing 40 of 99 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.